- Home
- Publications
- Publication Search
- Publication Details
Title
Managing Risks with Immune Therapies in Multiple Sclerosis
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-03
DOI
10.1007/s40264-018-0782-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis
- (2018) Caila Vaughn et al. CNS DRUGS
- Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
- (2018) Virginia Devonshire et al. JOURNAL OF NEUROLOGY
- 039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets
- (2018) Stuart Cook et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Understanding risk of PML through multiple sclerosis
- (2018) Roland Martin LANCET NEUROLOGY
- Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy
- (2018) Sebastian Rauer et al. NEUROLOGY
- Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
- (2018) Mika Saarela et al. NEUROLOGY
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- Natalizumab-Associated Primary Central Nervous System Lymphoma
- (2018) Menarvia Nixon et al. World Neurosurgery
- Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis
- (2018) L.J.W. Canham et al. Multiple Sclerosis and Related Disorders
- A case of immune-mediated encephalitis related to daclizumab therapy
- (2018) Michael Devlin et al. Multiple Sclerosis Journal
- Immune-mediated encephalitis with daclizumab: The final nail
- (2018) Thomas Williams et al. Multiple Sclerosis Journal
- Sarcoidosis following alemtuzumab treatment for multiple sclerosis
- (2018) Mark D Willis et al. Multiple Sclerosis Journal
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
- (2018) Sibyl Wray et al. Multiple Sclerosis Journal
- Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary progressive Multiple Sclerosis
- (2018) S.L. Hauser et al. Multiple Sclerosis and Related Disorders
- Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
- (2017) Marinella Clerico et al. Expert Opinion On Drug Safety
- Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
- (2017) Jagannadha Avasarala et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Alemtuzumab and de novo pulmonary arterial hypertension: A potential association?
- (2017) Laura Beaumier et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
- (2017) Aiden Haghikia et al. LANCET NEUROLOGY
- Ocrelizumab in multiple sclerosis: markers and mechanisms
- (2017) Reinhard Hohlfeld et al. LANCET NEUROLOGY
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
- (2017) Cyra E Leurs et al. Multiple Sclerosis Journal
- Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
- (2017) Adam F Carpenter et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
- (2017) Ingrid Meinl et al. Multiple Sclerosis Journal
- Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
- (2017) Jeffrey M. Gelfand et al. Neurotherapeutics
- Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?
- (2017) E.K. Van Obberghen et al. REVUE NEUROLOGIQUE
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
- (2017) María Inés Gaitán et al. JAMA Neurology
- Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
- (2017) Cyra E Leurs et al. Multiple Sclerosis Journal
- Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
- (2017) Adam F Carpenter et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
- (2017) Erin E Longbrake et al. Multiple Sclerosis Journal
- Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
- (2017) Ingrid Meinl et al. Multiple Sclerosis Journal
- Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
- (2017) Aaron E. Miller Therapeutic Advances in Neurological Disorders
- Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
- (2017) Cristina Guarnera et al. Therapeutics and Clinical Risk Management
- Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
- (2017) Jonas Graf et al. Annals of Clinical and Translational Neurology
- Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
- (2017) Jenny Link et al. PLoS One
- High cumulative JC virus seroconversion rate during long-term use of natalizumab
- (2016) A. Vennegoor et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study
- (2016) A. Miclea et al. JOURNAL OF NEUROLOGY
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS
- (2016) Steffen Pfeuffer et al. NEUROLOGY
- Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate
- (2016) Flaminia Purchiaroni et al. NEUROLOGY
- Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis
- (2016) Heidi N. Beadnall et al. NEUROLOGY
- PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
- (2016) Klaus Lehmann-Horn et al. NEUROLOGY
- Malignancies after mitoxantrone for multiple sclerosis
- (2016) Mathias Buttmann et al. NEUROLOGY
- Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod
- (2016) Amy K. Forrestel et al. JAMA Neurology
- Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
- (2016) Horst Penkert et al. JAMA Neurology
- Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
- (2016) Catherine Larochelle et al. Multiple Sclerosis Journal
- Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)
- (2016) Axel Meissner et al. Multiple Sclerosis and Related Disorders
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- (2016) Giancarlo Comi et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases
- (2016) Zaidoon Al-Jaderi et al. Frontiers in Immunology
- Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis
- (2016) Imke Metz et al. Acta Neuropathologica Communications
- Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
- (2015) Athina Papadopoulou et al. Expert Opinion On Drug Safety
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
- (2015) Daniela Rau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
- (2015) Hongxiu Luo et al. JOURNAL OF NEUROLOGY
- Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?
- (2015) Masahiro Mori JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
- (2015) Per Soelberg Sorensen et al. Therapeutic Advances in Neurological Disorders
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
- (2014) A. Gueguen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Dimethyl fumarate associated lymphopenia in clinical practice
- (2014) Erin E Longbrake et al. Multiple Sclerosis Journal
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
- (2014) C. Warnke et al. NEUROLOGY
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
- (2014) Paul Emery et al. PLoS One
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Progressive multifocal leukoencephalopathy in autoimmune diseases
- (2012) Elisabeth Palazzo et al. JOINT BONE SPINE
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
- (2012) Joshua Safran Therapeutics and Clinical Risk Management
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
- (2011) Jens Ingwersen et al. CLINICAL IMMUNOLOGY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
- (2011) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings
- (2011) Magnhild Sandberg-Wollheim et al. Multiple Sclerosis Journal
- Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
- (2011) Aaron Boster et al. Therapeutic Advances in Neurological Disorders
- Late-Onset Neutropenia After Rituximab Treatment
- (2010) Ofir Wolach et al. MEDICINE
- Sphingosine-1-phosphate receptor signalling in the heart
- (2009) C. K. Means et al. CARDIOVASCULAR RESEARCH
- Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice
- (2009) Ryou Fukushima et al. CONGENITAL ANOMALIES
- Interferon- mechanisms of action in multiple sclerosis
- (2009) S. Dhib-Jalbut et al. NEUROLOGY
- Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
- (2008) Megan Rahmlow et al. ARCHIVES OF NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Demko et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started